Name: United Therapeutics Corp (UTHR) News, Articles, Events & Latest Updates
Creator: Stocktwits

SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp. (SpaceX) designs, manufactures, and launches advanced rockets and spacecraft, including the fully reusable Starship and Super Heavy rocket system, targeting missions to Earth orbit, the Moon, Mars, and beyond. The company is based in Hawthorne, CA and has subsidiaries in Luxembourg and the United States. The company operates Starlink, a low-Earth orbit satellite constellation that delivers high-speed broadband internet worldwide. SpaceX is dedicated to advancing space technology with the goal of enabling human life on other planets. The company was founded in 2002 by Elon Reeve Musk, Kimbal Musk, Michael Kives. Elon Reeve Musk has been the CEO since 2002.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX is currently trending as investors weigh a significant earnings revenue beat against concerns over massive capital expenditures and the impending expiration of a large insider share lockup. The community is actively debating the stock's future, with bulls highlighting the long-term potential of Starlink and AI infrastructure, while bears point to high valuations and the risk of heavy selling pressure from employees and insiders.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is seeing intense community debate following an earnings report that featured record data center revenue and strong forward guidance, yet triggered a sell-off due to high investor expectations and concerns over increased capital expenditures. Bulls are highlighting long-term AI infrastructure growth and massive target price hikes as reasons to buy the dip, while bears argue the stock's valuation is stretched and that momentum is rotating toward competitors.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

iShares Silver Trust is trending as investors debate whether the recent pullback represents a buying opportunity or a deeper correction, with community sentiment split between technical analysis signals and long-term industrial demand driven by AI and green energy sectors. Discussions are heavily focused on the metal's role as a hedge against fiscal instability and inflationary pressures as participants watch for shifts in Federal Reserve policy and global manufacturing data.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is trending as investors weigh strong earnings momentum and a new $1 billion credit facility against broader software sector volatility. The community is actively debating the stock's long-term valuation potential in relation to its AI partnerships and its history of consistent quarterly beats.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Precigen is trending as the community debates its transition from a development-stage biotech to a commercial entity, driven by stronger-than-expected revenue figures and high short interest fueling anticipation of a potential squeeze. Investors are actively discussing the commercial success of its lead therapy, PAPZIMEOS, alongside the impact of upcoming clinical data and the potential for a long-term buyout.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is capturing investor attention as the market scrutinizes its competitive position and pipeline performance ahead of upcoming quarterly results. The community is actively debating the impact of legal challenges against rivals and the long-term potential of the oral Wegovy rollout amid mixed sentiment regarding the company's growth outlook.

EyePoint, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

EyePoint Inc.

EyePoint Pharmaceuticals Inc

EyePoint Pharmaceuticals is currently experiencing significant market attention and volatility driven by its ongoing Phase 3 LUGANO and LUCIA trials for its lead candidate, DURAVYU, in wet age-related macular degeneration. The community is actively debating the company's competitive positioning against rivals like Ocular Therapeutix, while closely monitoring clinical enrollment timelines and potential capital raising activities that have influenced recent price fluctuations.

AirJoule Technologies Corp. operates as a thermal energy and water harvesting technology company. It provides efficient and sustainable air conditioning and pure water from air through its transformational AirJoule technology. The company was founded on March 14, 2024 and is headquartered in Ronan, MT.

AirJoule Technologies Corp. - Ordinary Shares - Class A

AirJoule Technologies is trending as investors bet on the company's atmospheric water generation technology to solve water scarcity issues for rapidly expanding AI data centers. The community is closely watching the company's upcoming transition to commercialization and high-profile partnerships, with many discussing the long-term potential of the firm's decentralized water infrastructure despite recent volatility and dilution.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is trending as retail investors debate the stock's future amid a broader sector pullback, with bulls highlighting the company's commercial progress and government ties while bears point to high short interest and valuation concerns. The community is actively tracking potential catalysts, including a pending move to the Nasdaq and upcoming earnings, as they compare the stock's long-term potential against its recent volatility.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is facing intense scrutiny and volatility as investors react to the company's decision to overhaul its distribution strategy in China by cutting ties with thousands of third-party online sellers. While some view this as a necessary long-term move to regain pricing control and brand consistency, the community remains divided over the immediate revenue risks, leading to a polarized debate between those calling it a generational buying opportunity and others labeling the stock dead weight.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

UTHR or SDZNY: Which Is the Better Value Stock Right Now?

UTHR vs. SDZNY: Which Stock Is the Better Value Option?

Should You Invest in Liquidia Corporation Stock Ahead of Q2 Earnings? 

LQDA heads into its Q2 earnings with Yutrepia driving growth, rising profitability and a self-funded pipeline as investors watch quarterly performance.

Zoetis (ZTS) Reports Next Week: Wall Street Expects Earnings Growth

Zoetis (ZTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Published in The Lancet

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that The Lancet has published full results of its ADVANCE OUTCOMES study, available here. Ralinepag has not been approved for use in any indication by the FDA and remains investigational for PAH. Ralinepag...

Liquidia vs. United Therapeutics: Which PAH Stock Is the Better Buy Now?

Liquidia's Yutrepia launch is fueling rapid growth, outperforming United Therapeutics on estimates and share gains despite a higher valuation.

United Therapeutics Corporation Announces Appointment of Victor Dzau to its Board of Directors

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the companys Board of Directors appointed Victor Dzau, M.D., to its Board on July 22, 2026.This press release features multimedia. View the full release here...

United Therapeutics (UTHR) Earnings Expected to Grow: What to Know Ahead of Q2 Release

United Therapeutics (UTHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Can LQDA's Differentiated PAH Strategy Drive Long-Term Growth?

Liquidia's Yutrepia is driving strong growth with rapid commercial adoption as the company expands its pipeline and competes in the evolving PAH market.

United Therapeutics Corporation to Report Second Quarter 2026 Financial Results Before Market Open on Wednesday, August 5, 2026

United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its second quarter 2026 financial results in a press release that will be issued on Wednesday, August 5, 2026, at approximately 6:30 a.m. Eastern Time.United Therapeutics will host a public webcast on Wednesday...

Can LQDA's Yutrepia Drive Growth in the Competitive PAH Market?

LQDA's Yutrepia posts a strong commercial debut, but sustaining growth will hinge on standing out in the crowded PAH market as competition intensifies.

$UTHR Q1 '26 Earnings Results & Recap

• Reported GAAP EPS of $6.32 down -11.98% YoY
• Reported revenue of $781.5M down -1.62% YoY

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

United Therapeutics Corp

UTHR Holds As Tyvaso Shows 33% Lower Worsening Risk In Rare Lung Scarring Disease

Equity

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info